Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET
Company Participants
Louisa Stone - Manager, IR
Scott Myers - President and CEO
Kristian Humer - Chief Financial and Business Officer
Dr. Thomas Ciulla - Chief Development Officer
Todd James - SVP, Corporate Affairs and IR
Conference Call Participants
Derek Archila - Wells Fargo
Gavin Clark-Gartner - Evercore ISI
Thomas Smith - SVB Securities
Laura Chico - Wedbush Securities
Kalpit Patel - B. Riley Securities
Jason Butler - JMP Securities
Rami Katkhuda - LifeSci
Operator
Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the call over to Ms. Louisa Stone, Manager of Investor Relations for Viridian. Please go ahead.
Louisa Stone
Thank you, and welcome, everyone, to our first quarter 2023 earnings conference call. The press release reporting our financial results and corporate updates is available on the Investors page of our corporate website at www.viridiantherapeutics.com.
Joining me on the call this afternoon are Scott Myers, our President and Chief Executive Officer; Kristian Humer, our Chief Financial and Business Officer; Dr. Deepa Rajagopalan, our Chief Product and Strategy Officer; Dr. Thomas Ciulla, our Chief Development Officer; and Todd James, Senior Vice President, Corporate Affairs and Investor Relations.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook in addition to regulatory, product development and commercialization plans and research activities. These statements are subject to risks and uncertainties that could cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q and 10-K on file with the SEC. I would now like to turn the call over to Scott Myers, our President and CEO.
Scott Myers
Thank you, Louisa. Good afternoon, everyone. Thanks for joining us today. We had a productive quarter, and I'm excited to report on our progress today after completing my first 3 months as Viridian's President and CEO. 2023 is an important year for Viridian, a year that includes key milestones in all of our clinical programs. I am proud of all the progress our company has made thus far and looking forward to continuing our work to bring potential best-in-class therapies to patients with thyroid eye disease and additional disease areas in the future.